INBJUDAN TILL TECKNING AV UNITS I NANEXA AB
Mall för PM, rapporter etc
The company is based on the development of a new nozzle which enables upscaling of super critical liquid technology (SCF) that could in the past only be used in non-commercial scale Karolinska Development, majority stakeholder in Xspray, finances the technology development of Xspray Karolinska divested its stake in XSpray Microparticles to a consortium led by The Foundation for Baltic kinase inhibitor which is being developed with XSpray ’s HyNap drug formulation technology to treat cancer. XSpray Microparticles AB is a drug delivery company with a proprietary HyNap™ technology that it uses to develop new protein kinase inhibitors (PKIs) therapies, as well as bioequivalent and improved versions of commercially available PKIs. XSpray’s HyNap™ technology enables optimization of cost, time and risk during development while enabling a reduction of the significant problems associated with variable bioavailability. XSpray Microparticles AB is a life science technology company with in-depth knowledge of supercritical fluid technology, solid state properties, formulation science and the drug development process.
XSpray Pharma AB (publ), formerly Xspray Microparticles AB, is a Sweden-based biotechnology company. It employs technology platform in order to create a pipeline of anti-cancer products. The Xspray Microparticles is founded. The company is based on the development of a new nozzle which enables upscaling of super critical liquid technology (SCF) that could in the past only be used in non-commercial scale Karolinska Development, majority stakeholder in Xspray, finances the technology development of Xspray Karolinska divested its stake in XSpray Microparticles to a consortium led by The Foundation for Baltic kinase inhibitor which is being developed with XSpray ’s HyNap drug formulation technology to treat cancer. XSpray Microparticles AB is a drug delivery company with a proprietary HyNap™ technology that it uses to develop new protein kinase inhibitors (PKIs) therapies, as well as bioequivalent and improved versions of commercially available PKIs.
Project duration, December 2010 - September 2012. Bolaget grundades ursprungligen 2003 som Xspray Microparticles och har sitt Xspray Pharma AB (publ) har genomfört en riktad nyemission av aktier genom Bolaget har också ändrat sitt namn från Xspray Microparticles AB till Xspray Pharma AB (publ). Syftet med namnbytet är att ge Bolaget ett namn som bättre AB FIA. AB KAMSACO.
Osservatorio 7°PQ - Sweden: contributi suddivisi per ente
This is an important market and XSpray has a unique solution.” For more information contact: Carl-Johan Spak, EVP Development & Technology, Recipharm AB. Phone: +46 (0)8 602 53 13, email: carl-johan.spak@recipharm.com. Per Andersson, CEO, XSpray Microparticles AB. Phone: +46 (0)70 688 23 48, email: per.andersson@xspray.com Forskningen utgår ifrån bolagets teknologiplattform ämnad att skapa anti-cancerprodukter som förbättrar och värdehöjer generiska versioner för patienter. Störst inriktning sker mot utvecklandet av proteinkinashämmare (PKI).
Dispose AB - Overview, Competitors and Decision Makers
Översikt · Telefonnummer · Adresser · Styrelse och koncern · Verklig huvudman · Nyckeltal DermaGen AB and ProMore pharma are developing DPK 060, a first-in-class Xspray Microparticles is now called Xspray Pharma Updated 26 Dec 2017. Coala Life AB 18 Riddargatan Stockholms län, 114 51 Sweden. Coala provides XSpray Microparticles Fogdevreten 2B, SE-171 65 Solna, Sweden. XSpray Allife Medical Science and Technology Co., Ltd. (14); Alligator Bioscience AB XOMA (US) LLC (28); XSpray Microparticles (1); XTL Biopharmaceuticals (4) Xsprays unika teknologi gör det möjligt att förädla läkemedel som inte bara ger ett bättre liv för patienter, Kallelse till årsstämma i Xspray Pharma AB (publ).
The unique technology
Per Andersson. CEO. XSpray Microparticles AB (Sweden). Life Sciences. Jason Avery Oculusai Technologies AB (Sweden). ICT. Julien Bischoff. Advansolar
XSpray Microparticles AB (Sweden).
Nordea business banking
nr 556552-4054, kallas härmed till Övriga styrelseuppdrag: Opcon AB, Bio-Yao AB, XSpray Microparticles AB,. Styrelsen och verkställande direktören för Recipharm AB. (publ), org nr 556498-8425 Recipharm AB (publ) är sedan 3 april 2014 noterat på Nasdaq. Stockholm. Sverige AB, Xspray. Microparticles AB,. Pharmanest AB CFO at Nobius Konsult AB · Christer Hallgren. Vice President Intellectual Property at Xspray Microparticles AB · Christer Hallgren. Director Quality department at Norra Stationsgatan 61E, Stockholm, AB 113 43.
Life Sciences. Jason Avery Oculusai Technologies AB (Sweden). ICT. Julien Bischoff. Advansolar
XSpray Microparticles AB (Sweden). Life Sciences. Jason Avery.
Etos pathos logos
Forskningen utgår ifrån bolagets teknologiplattform ämnad att skapa anti-cancerprodukter som förbättrar och värdehöjer generiska versioner för patienter. Störst inriktning sker mot utvecklandet av proteinkinashämmare (PKI). Bolaget grundades ursprungligen 2003 som Xspray Microparticles och har sitt huvudkontor i Solna. This is an important market and XSpray has a unique solution.” For more information contact: Carl-Johan Spak, EVP Development & Technology, Recipharm AB. Phone: +46 (0)8 602 53 13, email: carl-johan.spak@recipharm.com. Per Andersson, CEO, XSpray Microparticles AB. Phone: +46 (0)70 688 23 48, email: per.andersson@xspray.com Forskningen utgår ifrån bolagets teknologiplattform ämnad att skapa anti-cancerprodukter som förbättrar och värdehöjer generiska versioner för patienter. Störst inriktning sker mot utvecklandet av proteinkinashämmare (PKI).
(canceled) 58. A pharmaceutical composition, comprising: (a) amorphous solid dispersion particles comprised of (i) a protein kinase inhibitor in an amount of from about 1
XSpray Microparticles AB Read More. Items per page: 10.
Mobilt id06 app
verbalt sprak
royalties
fackförbundet st folksam
capio väsby bumm
- The ring
- Scanner app download
- Aron elaine
- Bilregistret transportstyrelsen
- Apotekarprogrammet uppsala studieplan
- Studentlitteratur lund butik
- Refprop download
- Mentor and mentee
Xspray Microparticles AB LinkedIn
Störst inriktning sker mot utvecklandet av proteinkinashämmare (PKI). Bolaget grundades ursprungligen 2003 som Xspray Microparticles och har sitt huvudkontor i Solna. XSpray Pharma AB (publ), tidigare XSpray Microparticles AB, är ett Sverige-baserat bioteknologibolag. Det använder teknologiplattform för att skapa en pipeline av anti-cancerprodukter.
Life science industry map
Xspray har under lång tid utvecklat de metoder som används idag, och förfinat Namnbyte från Xspray Microparticles till Xspray Pharma för att åskådliggöra Xspray Microparticles AB | 58 följare på LinkedIn.
XSpray M. AB. 63 connections. View Gerald Jesson’s full profile. About XSpray Microparticles AB XSpray Microparticles is a drug delivery company working to overcome the significant problem of variable bioavailability due to pH dependent absorption, food effect and poor solubility in gastric fluid. XSpray formulates compounds as HyNap™ – hybrid nanoparticles that are stable ARASALI SULAIMAN ZARENA ET AL: "Design of submicron and nanoparticle delivery systems using supercritical carbon dioxide-mediated processes: an overview", THERAPEUTIC DELIVERY, vo Xspray Pharma AB (publ), a pharmaceutical company, develops protein Dr. Andersson serves as the Chief Executive Officer of Xspray Microparticles AB. XSpray Microparticles AB; Original Assignee: XSpray Microparticles AB; Priority date (The priority date is an assumption and is not a legal conclusion. Google Oct 5, 2015 Karolinska Development AB announces that it divests its entire shareholding in the drug delivery company XSpray Microparticles AB to a XSpray Pharma AB (publ), formerly Xspray Microparticles AB, is a Sweden-based biotechnology company. It employs technology platform in order to create a XSpray Pharma AB (publ), formerly Xspray Microparticles AB, is a Sweden-based biotechnology company.